Top Health Tech Companies in Washington, DC (203)

Strong Revenue Growth: Inc. 5000 recognitions cite 82% and 72% three-year growth, and investor disclosures note meaningful 2025 revenue scale, indicating sustained multi-year expansion. While precise YoY rates aren’t public, repeated list appearances and disclosed scale point to continued momentum.

Investor Backing & Capital Strength: Nordic Capital became the majority owner in 2025 to support the next phase of growth, expansion, and platform investment. Additional financing and stated plans for strategic acquisitions further reinforce access to growth capital.

Market Expansion: Customer and data footprint expanded to 170M+ patient records across 200+ provider/payer organizations, with more than 2.25M value-based lives added in 2024. Management and media describe ambitions for further expansion via M&A and potential moves beyond the U.S.

Strong Revenue Growth: Revenue is rising at a double‑digit pace across 2025 and into 2026, with consistent year‑over‑year gains. Galleri test volumes and screening revenue also increased, signaling sustained commercial momentum.

Market Expansion: Access is broadening through major EHR integrations and a growing provider network, alongside initiatives to enter new geographies. These moves extend reach beyond core channels and support continued adoption.

Investor Backing & Capital Strength: Capital raises and a sizable cash position provide a multi‑year runway to fund commercialization, trials, and regulatory efforts. Strategic financings with prominent partners reinforce the ability to invest through scale‑up.

Strong Revenue Growth: Revenue is rising at double-digit rates across recent periods, and management has increased full-year guidance, underscoring continued momentum. Growth is visible in both recent quarters and the prior year, indicating sustained top-line expansion.

Diversified Revenue Streams: Both Diagnostics and Data & Applications are expanding, with data-licensing/Insights activity increasing alongside clinical testing volumes. This mix reduces reliance on a single line of business and supports multiple growth vectors.

Strategic Partnerships: Collaborations with major biopharmaceutical companies and broader rollouts of platforms such as Next signal expanding commercial reach. Announced initiatives like a large whole‑genome dataset and work with firms including Merck reinforce external demand for the platform.

Strong Revenue Growth: Optum’s consolidated revenue expanded from $253.0B in 2024 to $270.6B in 2025, indicating continued top-line growth. Multi‑year reporting also highlights ongoing increases at the consolidated level even as segment performance diverges.

Diversified Revenue Streams: Performance is spread across three businesses, with Optum Rx delivering substantial gains, Optum Insight growing modestly, and Optum Health contracting. This mix shows pharmacy and technology services helping sustain overall scale despite softness in care delivery.

Cost & Operational Efficiency: Operating performance improved in 2026 as Optum’s operating income rose year over year to about $4B in Q2 alongside reported gains in technology and clinical operations. UnitedHealth also raised its 2026 adjusted EPS outlook, signaling confidence in execution.

Strong Market Position & Advantage: Feedback suggests Evolent is widely viewed as a front‑runner in value‑based specialty care, with an integrated multi‑specialty platform across oncology, cardiology, MSK, imaging and genetics. Evidence includes national payer traction (e.g., Aetna, Humana, Highmark) and operational embedding in plan manuals and bulletins.

Market Expansion: Feedback suggests recent signings and rollouts indicate continued expansion, including a ~4.5M‑lives advanced imaging contract and a Performance Suite expansion projected to add over $200M in annual revenue. Management also highlighted approximately $900M of new Performance Suite revenue slated to launch in 2026 and on‑time launches at major plans.

Future-Ready Strategy: Feedback suggests the company sharpened its focus by divesting primary‑care/ACO assets to concentrate on specialty condition management and by advancing evidence‑based pathways and navigation beyond traditional utilization management. Industry moves to streamline prior authorization are acknowledged, and the platform’s emphasis on outcomes, automation and multi‑specialty integration aligns with this shift.

Market Expansion: Multiple facility openings and approved projects across Arlington and Fairfax County signal active geographic and service-line growth, including a new outpatient pavilion, a planned freestanding emergency/urgent care site, and a behavioral health/rehab campus. Feedback suggests these additions broaden access and extend the system’s footprint beyond its core campus.

Investor Backing & Capital Strength: A multi-year capital plan supported by recent tax-exempt bond financing and affirmed strong credit ratings indicates capacity to fund expansions and weather near-term pressures. Public materials describe continued access to capital aligned with large campus renovations and new sites.

Strong Brand Reputation: Consistent recognition from CMS, U.S. News, Newsweek, the Leapfrog Group, and Healthgrades points to sustained quality, safety, and patient experience performance. Accreditations such as Magnet designation, Level II Trauma, and Commission on Cancer commendation reinforce credibility in the regional market.

Strong Market Position & Advantage: Market presence is characterized by recognition among the largest healthcare staffing firms and leadership accolades, suggesting a durable competitive standing in specialized healthcare workforce solutions.

Strategic Partnerships: Expansion through notable acquisitions such as Kelly Healthcare Resources and large-scale federal contracting vehicles reflects effective external alliances that extend service breadth and scale.

Strong Brand Reputation: Certifications like The Joint Commission Gold Seal and ISO 22956:2021, along with alignment to Baldrige principles, point to a reputation grounded in quality and operational rigor.

Market Expansion: Announcements detail acquisitions and a drumbeat of new hospitals, emergency departments, and clinics across multiple states, extending Mercy’s reach in core markets. Activity includes reopening sites and adding specialty capacity, pointing to continued geographic and service growth.

Strategic Partnerships: Multi‑year affiliations with the Alice L. Walton Foundation/Heartland Whole Health Institute (with Cleveland Clinic collaboration) and a 10‑year data alliance with Mayo Clinic are positioned to expand specialty access and enable data‑driven care at scale. These long‑horizon collaborations signal durable external support for growth initiatives.

Profitability: Recent system updates note a return to operating gains in FY2024 and improvement through parts of FY2026, providing a base to fund expansion. Reported rebounds following earlier losses indicate improving financial stability.